SGEN
$68.99
Seattle Genetics
($1.46)
(2.07%)
SGEN
Earnings Whisper ®
N/A
2nd Quarter June 2018
Consensus:  ($0.34)
Revenue:  $139.99 Mil
Thursday
Jul 26
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SGEN reports earnings?
Beat
Meet
Miss

Where is SGEN's stock price going from here?
Up
Flat
Down
Stock chart of SGEN
Analysts
Summary of analysts' recommendations for SGEN
Score
Grade
Pivots
Resistance
$73.80
$72.64
$70.82

$69.66

Support
$67.84
$66.68
$64.86
Tweet
Growth
Description
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS? (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME.
Peers
BiogenGilead SciencesBluebird BioAmgenNeurocrine BiosciencesQiagen N.V.Bio-TechneBioCryst PharmaceuticalsNovavaxRepligen